BR112014025339A2 - Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo - Google Patents

Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo

Info

Publication number
BR112014025339A2
BR112014025339A2 BR112014025339A BR112014025339A BR112014025339A2 BR 112014025339 A2 BR112014025339 A2 BR 112014025339A2 BR 112014025339 A BR112014025339 A BR 112014025339A BR 112014025339 A BR112014025339 A BR 112014025339A BR 112014025339 A2 BR112014025339 A2 BR 112014025339A2
Authority
BR
Brazil
Prior art keywords
prevention
reduction
treatment
pharmaceutical composition
same
Prior art date
Application number
BR112014025339A
Other languages
English (en)
Other versions
BR112014025339A8 (pt
Inventor
Ngambo Lisa A Purcell
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014025339A2 publication Critical patent/BR112014025339A2/pt
Publication of BR112014025339A8 publication Critical patent/BR112014025339A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BR112014025339A 2012-04-16 2013-04-15 método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. BR112014025339A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624519P 2012-04-16 2012-04-16
US201361759469P 2013-02-01 2013-02-01
PCT/US2013/036522 WO2013158516A1 (en) 2012-04-16 2013-04-15 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

Publications (2)

Publication Number Publication Date
BR112014025339A2 true BR112014025339A2 (pt) 2013-10-24
BR112014025339A8 BR112014025339A8 (pt) 2018-01-16

Family

ID=48184523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025339A BR112014025339A8 (pt) 2012-04-16 2013-04-15 método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.

Country Status (14)

Country Link
US (1) US9498529B2 (pt)
EP (2) EP3536342A1 (pt)
JP (2) JP6446355B2 (pt)
KR (1) KR20150008383A (pt)
CN (1) CN104244978A (pt)
AU (2) AU2013249577A1 (pt)
BR (1) BR112014025339A8 (pt)
CA (2) CA3219083A1 (pt)
HK (1) HK1202817A1 (pt)
MX (1) MX2014012285A (pt)
NZ (1) NZ631105A (pt)
SG (1) SG11201405163RA (pt)
WO (1) WO2013158516A1 (pt)
ZA (1) ZA201406194B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886958T3 (es) 2016-02-29 2021-12-21 Regeneron Pharma Roedores que tienen un gen TMPRSS humanizado
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
US10941213B2 (en) * 2018-01-26 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-TMPRSS2 antibodies and antigen-binding fragments
MX2022009476A (es) 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195119A1 (en) * 2020-03-24 2021-09-30 Corcept Therapeutics Incorporated Methods of reducing the risk of, severity of, and treating coronavirus infections
EP3964207A1 (en) 2020-09-02 2022-03-09 Christian-Albrechts-Universität zu Kiel Antiviral pharmaceutical composition for topical administration
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
KR101387781B1 (ko) * 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (ａｎｇｐｔｌ４) 에 대한단일클론 항체
US20070191322A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Microbial Compositions and Methods of Use
JP2008247864A (ja) * 2007-03-30 2008-10-16 Univ Of Tokushima モザイクセリンプロテアーゼ、ｍｓｐとその用途
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および／または予防薬
WO2010149549A1 (en) 2009-06-22 2010-12-29 Borealis Ag Automotive interior article with reduced smell
HUE058834T2 (hu) * 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz

Also Published As

Publication number Publication date
MX2014012285A (es) 2015-04-13
EP2838558A1 (en) 2015-02-25
EP3536342A1 (en) 2019-09-11
JP6446355B2 (ja) 2018-12-26
CA2869010A1 (en) 2013-10-24
KR20150008383A (ko) 2015-01-22
CA3219083A1 (en) 2013-10-24
BR112014025339A8 (pt) 2018-01-16
AU2018200265A1 (en) 2018-02-01
HK1202817A1 (en) 2015-10-09
US9498529B2 (en) 2016-11-22
WO2013158516A1 (en) 2013-10-24
AU2018200265B2 (en) 2019-07-18
US20130273070A1 (en) 2013-10-17
ZA201406194B (en) 2016-08-31
SG11201405163RA (en) 2014-09-26
AU2013249577A1 (en) 2014-10-02
JP2015516975A (ja) 2015-06-18
NZ631105A (en) 2016-09-30
CN104244978A (zh) 2014-12-24
JP2018048169A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
HK1220935A1 (zh) 治療乙型肝炎病毒感染的方法和藥物組合物
BR112014025339A2 (pt) Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
BR112014002619A2 (pt) composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
BR112013011737A2 (pt) composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
EP2802252A4 (en) METHODS AND DEVICES FOR PREVENTING INFECTIONS OF SURGICAL SITES
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112013015771A2 (pt) derivados de ciclosporina para o tratamento e a prevenção de uma infecção viral
EP2928470A4 (en) THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES REQUERIDAS US 61/624,519 DE 16.04.2012 E US 61/759,469 DE 01.02.2013, POIS POSSUI DEPOSITANTE DIFERENTE DO INFORMADO NA ENTRADA NA FASE NACIONAL E SUA RESPECTIVA CESSAO FOI APRESENTADA EM 28/04/2016 APOS O PRAZO REGULAR DE 60 DIAS PARA SUA APRESENTACAO, QUE TERMINAVA EM 10/12/2014, MOTIVO PELO QUAL SERA DADA PERDA DESTA PRIORIDADE, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O.

B12F Other appeals [chapter 12.6 patent gazette]

Free format text: RECURSO: 870210080704 - 01/09/2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]